Key result
Pacemaker implantation for AVB of unknown aetiology in patients <50 years was associated with a higher risk of death, heart failure, or arrhythmias versus controls.
Why the study?
Atrioventricular block of unknown aetiology is rare in young individuals, and long-term morbidity and mortality outcomes in these patients are unknown.
Does atrioventricular block of unknown aetiology treated with a pacemaker increase the risk of death, heart failure hospitalization, ventricular tachyarrhythmia, or cardiac arrest compared to matched controls in young patients?
Cohort (n=5,687)
Yes
Does atrioventricular block of unknown aetiology treated with a pacemaker increase the risk of death, heart failure hospitalization, ventricular tachyarrhythmia, or cardiac arrest compared to matched controls in young patients?
Young patients with atrioventricular block of unknown aetiology requiring a pacemaker have a significantly higher long-term risk of death, heart failure, and severe arrhythmias compared to matched controls.
Answers are grounded in this paper and cite their sources.
Supports closer surveillance in young patients with unexplained AVB; leaves open whether occult cardiomyopathy drives excess risk.
AIMS: Atrioventricular block (AVB) of unknown aetiology is rare in the young, and outcome in these patients is unknown. We aimed to assess long-term morbidity and mortality in young patients with AVB of unknown aetiology. METHODS AND RESULTS: We identified all Danish patients younger than 50 years receiving a first pacemaker due to AVB between January 1996 and December 2015. By reviewing medical records, we included patients with AVB of unknown aetiology. A matched control cohort was established. Follow-up was performed using national registries. The primary outcome was a composite endpoint consisting of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation. We included 517 patients, and 5170 controls. Median age at first pacemaker implantation was 41.3 years [interquartile range (IQR) 32.7-46.2 years]. After a median follow-up of 9.8 years (IQR 5.7-14.5 years), the primary endpoint had occurred in 14.9% of patients and 3.2% of controls [hazard ratio (HR) 3.8; 95% confidence interval (CI) 2.9-5.1; P < 0.001]. Patients with persistent AVB at time of diagnosis had a higher risk of the primary endpoint (HR 10.6; 95% CI 5.7-20.0; P < 0.001), and risk was highest early in the follow-up period (HR 6.8; 95% CI 4.6-10.0; P < 0.001, during 0-5 years of follow-up). CONCLUSION: Atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. Patients with persistent AVB were at higher risk. These findings warrant improved follow-up strategies for young patients with AVB of unknown aetiology.
No takes yet. Share an insight, caveat, or question.
Dideriksen et al. (2021) conducted a cohort in Atrioventricular block of unknown aetiology (n=5,687). Pacemaker implantation for AVB of unknown aetiology vs. Matched control cohort was evaluated on Composite of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation (HR 3.8, 95% CI 2.9-5.1, p=< 0.001). Pacemaker implantation for AVB of unknown aetiology in patients <50 years was associated with a higher risk of death, heart failure, or arrhythmias versus controls.
Synapse has enriched 10 related papers. Consider them for comparative context: